Novo Nordisk Wins EU Nod for Haemophilia Drug While Lilly Steals a March in Australia's Weight-Loss Pill Race
Published on 11/17/2026 at 14:41 | Editorial boerse-global.deNovo Nordisk secured European Commission approval on Friday for FREHEMGO (denecimig), cleared for routine bleeding prevention in adults and children with haemophilia A, including patients with and without inhibitors. The Danish drugmaker expects to roll the therapy out in the first European countries next year — a staged launch covering part of the continent rather than a simultaneous, bloc-wide debut.
The haemophilia green light lands alongside a crowded regulatory and commercial calendar. Novo has filed for Etavopivat with both the US Food and Drug Administration and the European Medicines Agency, seeking clearance to treat sickle cell disease in adolescents and adults aged twelve and older; decisions are anticipated in 2027.
Australia: Approval Is One Thing, Shelf Presence Another
Half a world away, the battle for the weight-loss pill market is being decided on logistics rather than paperwork. Australia's TGA has approved Lilly's Foundayo, according to a report from broadcaster Nine, following the November clearance of Novo's Wegovy tablet. The distinction that matters for investors sits in the delivery dates: Foundayo is expected on shelves within days, while Wegovy will not reach the market until the end of 2026.
That gap turns attention from regulatory milestones to actual commercial execution. Foundayo carries approval in Australia for both weight management and type-2 diabetes, with a reported monthly price of AUD 250–370 depending on dose. The Wegovy tablet, by contrast, carries a recommended monthly price of AUD 260–395, according to the Australian Financial Review — a list recommendation rather than a statement of realised sales.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Reimbursement shapes the contest further. Australia's PBS generally does not subsidise GLP-1 medicines prescribed purely for weight loss, and both tablets are prescription-only, so out-of-pocket pricing becomes a central competitive lever. Dosing routines differ as well: Foundayo can be taken at any time of day, whereas the Wegovy pill must be swallowed in the morning on an empty stomach. Neither detail on its own predicts commercial success, though both form part of the concrete profile of the two offerings.
CagriSema Data Builds the Case for What Comes Next
Behind the Australian skirmish, Novo is assembling the clinical groundwork for its next-generation obesity franchise. At ObesityWeek 2026 the company presented Phase 3 REDEFINE 9 results for CagriSema, still in development, showing the two lower-dose regimens delivered estimated average weight loss of 20.7% and 21.0% after 68 weeks. Those figures assume participants adhered to treatment; under the same assumption, the placebo arm recorded 2.0% weight loss. The findings were also published in The Lancet Diabetes & Endocrinology.
Paediatric data arrived through STEP Young, a Phase 3 trial of investigational semaglutide in children with obesity aged six to under twelve. Nearly 80% of participants cut their body-mass index by at least 10%, a threshold no child in the placebo group reached.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
CagriSema, designed as a successor to Wegovy by combining GLP-1 with amylin, now awaits an FDA decision on weight control expected in the fourth quarter of 2026, with a US launch pencilled in for early 2027 subject to approval. The ObesityWeek readouts supply clinical context for that filing but substitute for neither the regulator's verdict nor the commercial rollout that would follow.
For shareholders, the picture splits cleanly in two. In Australia, approval is banked and the next tests are availability, price and access. For CagriSema, the FDA's call remains the gate. The Australian supply timeline and the expected US decision now stand as the most tangible near-term markers of Novo's push to broaden its weight-management portfolio.
Ad
Novo Nordisk Stock: New Analysis - 17 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
